

Gene Expression and TB Pathogenesis in Rhesus Macaques: *TR4*, *CD40*, *CD40L*, *FAS* (*CD95*), and *TNF* are host genetic markers in peripheral blood mononuclear cells that are associated with severity of TB lesions

Morteza Roodgar^{1,*}, Cody T. Ross², Ross Tarara³, Linda Lowenstine⁴, Satya Dandekar⁵, David Glenn Smith^{1,2,3}

Abstract

Tuberculosis (TB) pathologic lesions in rhesus macaques resemble those in humans. The expression levels of several host TB candidate genes in the peripheral blood mononuclear cells (PBMCs) of six rhesus macaques experimentally infected with *Mycobacterium tuberculosis* were quantified pre-infection and at several dates post-infection. Quantitative measures of TB histopathology in the lungs including: granuloma count, granuloma size, volume of granulomatous and non-granulomatous lesions, and direct bacterial load, were used as the outcomes of a multi-level Bayesian regression model in which expression levels of host genes at various dates were used as predictors. The results indicate that the expression levels of *TR4*, *CD40*, *CD40L*, *FAS* (*CD95*) and *TNF* in PBMC were associated with quantitative measures of the severity of TB histopathologic lesions in the lungs of the study animals. Moreover, no reliable association between the expression levels of *IFNE* in PBMCs and the severity of TB lesions in the lungs of the study animals was found. In conclusion, PBMC expression profiles derived from the above-listed host genes might be appropriate biomarkers for probabilistic diagnosis and/or prognosis of TB severity in rhesus macaques.

© 2011 Infection, Genetics, and Evolution

Keywords: Tuberculosis (TB), rhesus macaques, gene expression, host genes, histopathologic lesions, *TR4*, *IFNE*

1. Introduction

Tuberculosis (TB) is a zoonotic disease in primates caused by *Mycobacterium tuberculosis* (MTB). TB can exist *in vivo* in either active or latent form. Approximately 30% of the human population worldwide is latently infected with *Mycobacterium tuberculosis* (MTB), 5–10% of whom progress to active TB [1]. Nonhuman primates (NHPs), particularly rhesus and cynomolgus macaques infected by TB, exhibit clinical symptoms and histopathologic lesions similar to those of humans, making them more appropriate animal models for the study of human TB pathogenesis than other laboratory animals, such as mice [2, 3, 4]. However, since NHPs are not genetically homogenous, unlike

*Corresponding author

Email address: mroodgar@ucdavis.edu (Morteza Roodgar)

¹Graduate group of Comparative Pathology, University of California, Davis

²Department of Anthropology, University of California, Davis

³California National Primate Research Center (CNPRC), University of California Davis, Davis, CA 95616

⁴Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California Davis, Davis, CA 95616

⁵Medical Microbiology and Immunology, School of Medicine, University of California Davis, Davis, CA 95616

the mice used in biomedical research, the results of case-control studies of TB in NHPs might be confounded by the genetic heterogeneity of the study animals [5, 6].

This genetic heterogeneity in NHP study populations, which may lead to variation in clinical and histopathologic outcomes for TB, could, however, facilitate the identification of host genes (e.g. inducible nitric oxide synthase [*iNOS*] and nuclear factor kappa-light-chain-enhancer of activated B cells [*NFKB*]) that play key roles in various immune response against MTB in NHPs [7, 8]. Genes with altered expression levels as a result of TB exposure may be useful as host markers for probabilistic TB diagnosis in both humans and NHPs. Previous studies in human populations, *in vivo* mouse model experiments, and *in vitro* experiments, have identified several host candidate genes associated with susceptibility to TB [9]. Most of these genes encode key components in the innate immune response against MTB. These genes are represented in the following four categories: 1) genes encoding receptors that detect MTB (e.g. Toll-like receptor 2 [*TLR2*] and peroxisome proliferator-activated receptor gamma [*PPARG*]), 2) genes encoding pro-inflammatory cytokines and chemokines (e.g. interferon gamma [*IFNG*] and chemokine C-C motif ligand 2 [*CCL2*]), 3) genes encoding anti-inflammatory cytokines (e.g. interleukin-10 [*IL10*]), and 4) genes encoding enzymes that play key roles in intracellular immunity and the elimination of MTB inside macrophages (e.g. *iNOS*) [8, 10]. Current TB tests such as the tuberculin skin test (TST) and *IFNG* based assays lack sensitivity and/or specificity, and are logistically difficult for patients and/or laboratories involved. For example, rhesus macaques with several consecutive negative TST results are sometimes found to be TB positive following pathologic investigations at necropsy [11, 12].

The goal of this study is to investigate the associations between the expression levels of a selected group of host innate immune response genes in the peripheral blood mononuclear cells (PBMC) of rhesus macaques (pre- and post-MTB infection) and the severity of TB pathogenesis. The selection of the host candidate genes in the present study was based on a comprehensive literature review and includes: *PPARG* [13], nuclear receptor subfamily 2 group C member 2 (*NR2C2*) also known as testicular receptor 4 (*TR4*) [13], *IFNE* [14, 15, 16], *CD40* [17, 18], chemokine C-X-C motif ligand 10 (*CXCL10*) also known as IFNG-inducible protein 10 (*IP10*) [19], *CSF2* [20, 21], *CD40L* [22, 23, 24], *IL7* [25, 26, 27], *IL15* [28, 29], *FAS* (*CD95*) [30], *IL23A* [31, 32], *IL12A* [33, 34, 35, 36, 24], *IL13* [37], *IL4* [38, 39, 40, 36], *IL5*, solute carrier family 11 member 1 (*SLC11A1*) also known as natural resistance-associated macrophage protein (*NRAMP1*) [41, 42, 43, 44, 45, 46], *TLR2* [47, 48], *FASL* [49], *IL17A* [50, 51], *CCL2* [52, 53, 54, 55], tumor necrosis factor- α (*TNF*) [34, 56], nitric oxide synthase 2A (*NOS2A*) also known as *iNOS* [57, 58, 10, 59, 60], and dendritic cell-specific intercellular adhesion molecule-3-Grabbing non-integrin (*DCSIGN*) also known as *CD209* [61, 62].

Previous studies involving human subjects, *in vivo* mouse model experiments, and *in vitro* cell cultures have shown that the expression of these genes may be associated with TB pathogenesis. For instance, it has been recently shown through *in vitro* experiments that *PPARG* and *TR4* play key roles in the pathogenesis and survival of MTB within macrophages [13]. However, few *in vivo* studies have demonstrated the role of these new candidate genes in MTB pathogenesis. The role of some other genes in the above list have been described in *in vitro* and *in vivo* model experiments.

Since the course of TB infection in rhesus macaques is similar to that in humans, and it is possible to perform controlled MTB experimental infection in rhesus macaques, the change in expression levels of various genes in the PBMCs of the laboratory animals can be assayed at different dates pre- and post-infection. The genes with highly divergent expression levels (pre- and post-infection) as a function of the presence and severity of TB lesions in lungs may be useful as host biomarkers in probabilistic TB diagnostic methods, especially for the diagnosis of latent TB cases in which direct isolation of MTB can not be easily conducted.

In this study, six rhesus macaques were experimentally infected with MTB [63]. Blood samples from the infected animals were obtained pre-infection and at different dates (every 1–2 months) after MTB infection. The study animals were euthanized approximately six months post-infection and gross necropsy and histopathological investigations were conducted. A quantitative assessment of the severity of lesions in the lungs and other organs was determined using several measures of TB pathogenesis: 1) number of granulomas, 2) size of the largest granuloma, 3) volume of the lung tissue exhibiting granulomatous lesions, 4) volume of the lung tissue exhibiting non-granulomatous lesions, and 5) a direct count of bacterial load in the lungs, in colony forming units (CFUs). A comprehensive morphometric/quantitative description of the histopathologic lesions of MTB in the lungs of all study animals was previously reported in detail [63].

We identify several host TB candidate genes whose upregulation or downregulation in the PBMCs of the study animals is associated with the severity of lesions in the lung tissues of the study animals, as discussed below. Similar approaches for identification of the expression profiles of candidate genes have been previously used for prognosis of

cancer and autoimmune diseases [64].

2. Results

2.1. Model Results

We find consistent secular trends across animals in the expression levels of *CCL2*, *FASL*, *IL10*, and *TNF* as TB infection develops over time (Figure 1). This provides evidence that experimental infection with TB can lead to changes in the expression levels of these genes. As such, a multi-gene panel which assays expression levels of these genes might be useful for distinguishing non-infected macaques from infected ones. However, these results are not sufficient to comment on the relationship between gene expression levels and TB severity; to do that, we must explicitly model the relationship between gene expression and TB severity at time of euthanasia, as in Figure 2.

Elevated expression levels of *IP10* (*CXCL10*), *TLR2*, *TR4*, and *TNF* in the PBMCs of the study animals before MTB infection are reliably associated with the severity of TB lesions and the bacterial count of MTB in the lungs of the study animals months later (Figure 2). These genes can be categorized as the group of genes whose expression levels pre-infection in this sample are associated with susceptibility to TB.

Further, we find that the relationship between expression levels of *CD40*, *CD40L*, *CD95*, *TNF*, and especially *TR4* changes from the pre-infection state to the post-infection state (Figure 2). These genes can be categorized as the group of genes whose expression levels may be indicative of TB severity.

PPARG, *CSF2*, *IL23A*, *IL12A*, *IL13*, *IL4*, *IL5*, *IL17A*, and *iNOS*, could not be quantified in all animals (we could not distinguish between a true lack of expression and problems in quantification), so these genes were excluded from the study.

To visually represent the strength and direction of the relationship between gene expression levels and TB pathogenesis, we plot the values of the regression coefficient estimates in Figure 2. The numerical values and posterior confidence intervals of these parameter estimates are included in the Supplementary Materials.

2.2. Information Theoretic Model Comparison

The sample size of animals in this study is small ($N = 6$); however, independent assessments of TB severity were conducted in each of ($L = 6$) lung lobes (left caudal, left cranial, right accessory, right cranial, right caudal, and right middle), allowing for the relationship between gene expression and TB pathogenesis to be assessed in six semi-independent tissues per animal, meaning the actual sample size of outcome data is 36. Prior to the development of multi-level models and Bayesian analysis, issues of pseudoreplication would rendered nuanced analysis of such data unfeasible [65]. However, by developing a custom multi-level statistical model, we can analyze the data using methods designed specifically for cases where observations (eg. granuloma counts, max granuloma size, and granuloma volume per lung lobe) are clustered into higher-level units (animals), which may introduce correlations in outcomes at the lower level.

To test if use of gene expression data actually improve predictive inference relative to a null intercept-only model, we use information theoretic model comparison [66]. These methods allow us to demonstrate that models using gene expression information have significantly better predictive ability than the null model (Figure 3). This analysis provides evidence that although our sample size is small in terms of animals, there is strong enough signal in our data to make model-based predictive inference possible.

We use information theoretic model comparison to assess the relative utility of gene expression levels at each date, in each measure of TB pathogenesis. The results of model comparison are represented visually in Figure 3, and numerically in the Supplementary Materials. Across all measures and time periods, the null model has almost no information theoretic support, which provides strong evidence that use of gene expression levels improves predictive inference concerning TB severity. There is some variation in which genes have the most predictive ability at each date (for example, *TNF* expression levels shortly after infection are among the best predictors of TB severity, but *TR4* and *CD40* expression levels at later dates are better predictors of TB severity). There are also genes which are consistently of little use in predicting TB severity (e.g. *IFNE*, *IL10*, and *IL15*).

2.3. Gene by Gene Profiles

Elevated expression levels of *TNF* in the PBMCs of the study animals pre-infection is associated with increased severity of TB infection at time of the euthanasia of the study animals 5–6 month post-infection (Figure 2j). However at the date of 4-01-2009 and at necropsy, *TNF* expression levels were inversely associated with TB severity (Figure 2j).

A similar pattern was observed for *CD40* and *CD40L*, whose expression levels become inversely associated with TB severity at euthanasia around 02-03-2009 or 03-02-2009 (Figures 2b and 2c). *CD95* expression levels become inversely associated with TB severity at 02-03-2009 (Figure 2d). As such, the expression levels of these four genes may contain information on the underlying severity of TB infection, and may be useful in probabilistically estimating TB severity from PBMC-based expression assays.

Elevated expression levels of *CCL2* pre-infection (11-05-2008) and (to some extent) one month post-infection (01-05-2009) show a weak but positive association with TB severity at time of the euthanasia; however, no reliable association between *CCL2* expression and TB severity after 01-05-2009 was observed (Figure 2a).

The expression levels of *IP10* both pre-infection (11-05-2008) and post-infection (01-05-2009 to 03-02-2009) show a strong positive association with TB severity at euthanasia (Figure 2g).

The expression levels of *IL7* and *IL15* show no reliable signs of association with TB severity at euthanasia (Figures 2f and 2l).

The expression levels of *IL10* and *IFNE* show no relationship to TB severity at euthanasia (Figure 3).

The pre-infection (11-05-2008) expression levels of *TR4* are positively associated with the severity of TB infection 5–6 months later. Furthermore, the expression levels of *TR4* become strongly inversely associated with TB severity by 02-03-2009, and remain this way until the animals were euthanized (Figure 2k).

Likewise, pre-infection (11-05-2008) expression levels of *TLR2* are positively associated with the severity of TB infection 5–6 months later (Figure 2i). However, the relationship remains positive until 03-02-2009, and thereafter shows no relationship with TB severity.

NRAMP1 expression levels pre-infection show no reliable association with TB severity (Figure 2h); however, expression levels of *NRAMP1* post-infection show a marginally reliable positive association with TB severity, especially in the months immediately prior to euthanization (04-01-2009 to euthanization).

Finally, expression levels of DC-SIGN failed to show signs of association with TB severity (Figure 3).

2.4. Histopathology

Figures 4 and 5 present the histopathology of granulomatous lesions in right caudal lobe of lungs in the study animals using hematoxylin and eosin and then trichrome blue staining, respectively. In general, granulomas with central area of necrosis and/or mineralized cavities are observed. Additionally, the margins of macrophages, lymphocytes, and rare multinuclear giant cells are surrounded by fibrous connective tissue. Smaller granulomas are noticed within and outside of the capsules. These results indicate that the encapsulation seems to be breached. The areas of necrosis were extensive in two animals that exhibited severe TB, necessitating euthanasia before scheduled termination of the study.

3. Discussion

The results of this study indicate that the expression levels of some host candidate genes both pre- and post-infection are associated with the severity of TB outcomes. Moreover, histopathological investigations found presence of TB lesions in organs other than the lungs (in brain and eye tissue). Quantitative morphometric measures of the histopathologic changes in the lungs of the study animals and other quantitative measures of severity of TB infection (e.g. bacterial load in lungs) were used as the outcomes of a statistical model in which the expression levels of the candidate genes in PBMCs were predictors. We have identified several genes (including the previously unverified *TR4*) whose expression levels in PBMCs post-infection are indicative of the severity of TB pathogenesis. These genes may thus be of use in a multi-gene expression panel for the probabilistic estimation of the likelihood of TB infection. No reliable association between the expression level of *IFNE* in PBMCs and the severity of TB lesions in the lungs of the study animals was found.

3.1. Gene Expression Levels as Biomarkers for TB Infection

Our results suggest that the genes *TR4*, *CD40*, *CD40L*, *CD95*, *IL10*, and *TNF* may be of use in the creation of a gene-expression panel for probabilistic estimation of TB infection. The information on some of the genes such as lipid sensing nuclear receptors (e.g. *TR4*) and IFN- ϵ are novel in an *in vivo* setting.

The study of TB pathogenesis in cynomolgus macaques may be better suited to study of human TB than the rhesus macaques used herein. Uniquely, cynomolgus macaques can progress to latent tuberculosis if infected with a low dose of MTB. This animal model has been utilized to investigate and categorize latent and active MTB infections at the molecular and histopathologic levels [67, 5, 2]. We did not have access to samples from TB infected cynomolgus macaques, however. It would be beneficial to compare and contrast our results to studies in which cynomolgus macaques are experimentally infected with TB, possibly using varying doses MTB at inoculation.

Studies similar to ours can not be conducted in human subjects due to ethical limitations; studies of gene expression in NHPs experimentally infected with TB are thus one of the best models for human TB [68]. However, findings in studies of gene expression and TB in NHPs can be compared to similar studies of human TB cases using other available (yet lower resolution) measures of TB severity (e.g. chest X-ray etc).

In this paper, we have not provided any evidence that the pattern of change in gene expression levels observed in this study is unique to TB infection as opposed to infection with a different pathogen. We recognize the necessity of future studies to investigate the uniqueness of gene expression changes in the above listed genes. However, we suspect that although the expression levels of any one gene are unlikely to be diagnostic of TB infection to the exclusion of other pathogens, an expression panel that includes many genes may be able to make such distinctions. Below we place our findings in the context of gene-specific research programs.

3.1.1. *TR4* and *PPARG*

Previous *in vitro* studies have shown that LSNRs (e.g. *PPARG* and *TR4*) play a key role in the survival of MTB in macrophages [13, 69]. In this study, we evaluated whether the expression levels of two LSNR genes (*TR4* and *PPARG*) in PBMCs of MTB infected rhesus macaques are associated with the severity of TB infection in the lungs. To the best of our knowledge, there have been no previous *in vivo* studies of these genes as predictive host markers of TB severity in NHPs or humans. Although we could not successfully quantify *PPARG* expression in the PBMCs of all the study animals, we did successfully quantify the expression levels of *TR4* in the PBMCs of all study animals.

We observe that elevated pre-infection expression levels of *TR4* are reliably associated with increased severity of TB at time of euthanasia; however, as infection develops over time, we observe an inverse relationship develop between *TR4* expression and TB severity. These results suggest that upregulation of *TR4* post-infection may play a role in attenuating TB pathogenesis. Furthermore, our results suggest that *TR4* may have a significant role as a new host biomarker/gene for inclusion in a diagnostic gene expression panel for TB infection.

3.1.2. *CD40*, *CD40L*, and *CD95*

It has been previously reported that *CD40* plays a key role in immune response against MTB and host genetic mutations can increase TB susceptibility by impairing *CD40* production [24]. Recent findings show that MTB infection induces expression of *CD40* in macrophages [70] and that the expression level of *CD40* in PBMCs increases with age in human infants, as the innate response against MTB develops [18].

Some *in vitro* and *in vivo* experiments indicate that *CD40L* induces an antimicrobial response to MTB infection [22, 23]; the results of the present study also suggest that the expression levels of *CD40L* in the PBMCs of the TB infected animals are inversely associated with the severity of tuberculosis, agreeing with the results from some previous studies in the mouse model [71, 17].

Additionally, MTB-reactive $\gamma\delta$ -T cells have been shown to express high levels of *FAS* (*CD95*) [72]. Our findings are thus in concordance with those from other studies of TB pathogenesis in animal models, which reported the importance of *FAS* (*CD95*) in a robust immune response against MTB [73, 74, 75, 76].

The inverse associations we observe develop between the expression levels of *CD40*, *CD40L*, and *FAS* (*CD95*) in PBMCs and the severity of TB in the study animals suggests that they might be appropriate host biomarkers for inclusion in an expression profile for the prediction of MTB infection in rhesus macaques.

3.1.3. *iNOS*

Previous studies have indicated that the expression level of *iNOS* at the site of granulomatous lesions in lung tissue, alveolar epithelial cells, and macrophages is relatively high in TB-infected individuals; specifically, the expression level of *iNOS* in the lungs of mice infected with MTB is high in the early phases of TB infection, during the formation of granulomas, and low in the late phases [10]. Since previous studies have shown that the expression levels of *iNOS* in the lung tissue of TB-infected/*Bcg* vaccinated macaques is significantly elevated, and since *iNOS* is thought to play an important role in intra-cellular immunity and the elimination of MTB in macrophages through the production of peroxynitrite, its expression levels in the PBMCs of study animals was also evaluated through the use of two (human and rhesus macaque) *NOS2A* probes [77, 78, 79, 80]. Unfortunately, the expression levels of *iNOS* could not be successfully quantified in the PBMCs of all rhesus macaques included in the present study. As such, future research is needed in order to evaluate the relationship between the expression level of *iNOS* in PBMCs of TB infected rhesus macaques and the severity of TB. Alternatively, research could focus on the development of methods that detect *iNOS* and/or nitric oxide (NO) metabolites [81].

3.1.4. *IP10*

It has been previously shown that polymorphisms in the promoter of *IP10* are associated with susceptibility to TB [82]. Moreover, *IP10* has been previously considered as a host candidate gene for TB susceptibility and a key marker for TB diagnosis [83, 84]. The results of this study indicate that the expression level of *IP10* (*CXCL10*) in PBMCs of TB infected rhesus macaques both pre- and shortly post-infection may be associated with increased TB severity.

3.1.5. *NRAMP1*

The occurrence of mutations in the *NRAMP1* gene and resultant susceptibility to TB has been extensively studied over the last 20 years. It was originally shown that mutations in the coding region of *NRAMP1* caused susceptibility to some *Mycobacterial* infections but not to *Mycobacterium tuberculosis* [42, 43, 44, 46, 45]. Recent studies, however, indicate an important role of *NRAMP1* in susceptibility to MTB [85, 86, 87], but there are not many studies that validate the predictive value of *NRAMP1* expression for estimating TB severity. The results of our study indicate that expression levels of *NRAMP1* post-infection show some positive association with TB severity, especially in the months immediately prior to euthanasia. The expression profile of *NRAMP1*, together with other genes that show an association with severity of TB lesions in the lung, might be valuable for prognosis of TB in NHPs and humans.

3.1.6. *IFNE*

Although *IFNG* has been extensively used as one of the most important host immune genes for TB pathogenesis, to the best of our knowledge there is not much information on the predictive role of *IFNE* for TB diagnosis and/or prognosis purposes. While the expression of *IFNG* has been previously shown to have predictive value in the diagnosis of TB in both humans and macaques, this study failed to find a relationship between the expression levels of the recently identified *IFNE* in the PBMCs of the study animals and severity of TB infection, suggesting that *IFNE* may not be an appropriate host gene/biomarker for the diagnosis of TB. Our study animals all exhibited the active form of TB and it would be useful to investigate the predictive value of *IFNE* in cynomolgus macaque that can develop latent TB when infected with low dose of MTB [5]. This will help us better understand the predictive value of this gene in latent TB cases.

3.1.7. Other Genes

Although several other host genes investigated in this study have been found to be functionally important genes or biomarkers in predicting severity of disease progression [see 88, 54] and expression levels of some of them in human samples (e.g. in Bronchioalveolar lavage and sputum) have been shown to correlate with the status of TB infection [36], we did not find associations between the expression levels of these genes in PBMCs and severity of TB in rhesus macaques.

There are several other immune-related candidate genes that could be included in a study with a larger sample size to assess the predictive ability of gene expression for TB diagnosis and prognosis. Killer immunoglobulin-like receptor (KIR) genes are one of many genes that could be included in a more comprehensive study [89]. Although some of the genes investigated in our study do not show reliable bivariate associations with the severity of TB in

NHPs, they might have significant roles in predicting TB outcomes when used in combination with other genes or when considering gene-gene interactions in the model. A larger sample size is required to investigate whether considering gene-gene interactions improves the predictive ability of gene expression for diagnosis and/or prognosis of TB in NHPs.

In conclusion, while the expression levels of the recently identified member of the interferon family, *IFNE*, was not reliably associated with severity of TB infection, the results of this study indicate that expression levels of *TR4*, *CD40*, *CD40L*, *FASC* (D95), and *TNF*, in the PBMCs of MTB-infected rhesus macaques are associated with severity of disease progression, and, as such, exhibit substantial potential as host biomarkers for inclusion in a diagnostic and/or prognostic expression profile for TB infection.

4. Methods

4.1. Study Subjects

Tissue samples remaining from a study of NHPs experimentally infected with TB at the California National Primate Research Center (CNPRC) for other purposes were used for this study [63]. The study subjects were six male rhesus macaques that were simian retrovirus D-negative and SIV-negative (four of pure Indian ancestry, two of mixed Indian-Chinese ancestry) and were colony-bred from the California National Primate Research Center (CNPRC) at the University of California, Davis [63, 90]. All study animals were housed and cared for according to the standards detailed in the Guide for the Care and Use of Laboratory Animals (National Research Council 1996). Protocols for the maintenance of animals were approved by the UC Davis Institutional Animal Care and Use Committee (IACUC). Animals were handled in accordance with Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) Standards [63].

4.2. MTB inoculation, blood sampling, and necropsy

As was explained previously [63], the study animals were inoculated with 500 CFU of MTB (Erdman strain, lot K01) in 3 ml of sterile saline through bronchoscopic inoculation using a BF-XP60 fiberoptic bronchoscope (Olympus, Tokyo, Japan) [63]. Blood samples from the study animals were drawn before MTB inoculation, as well as after inoculation at approximately one month intervals. PBMCs were isolated from whole blood immediately after blood samples were taken, and were stored in a -80°C freezer. PBMCs were isolated from blood samples one month before MTB inoculation (11-05-2008), at several dates post-inoculation (01-05-2009, 02-03-2009, 03-02-2009, 04-01-2009, and at the time of each animal's euthanasia). These PBMCs were used for the gene expression analysis in this study. However, since two of the six study animals progressed to severe TB and exhibited extreme clinical symptoms, they were euthanized for ethical reasons 9 weeks prior to the euthanasia of the other four study animals.

4.3. PBMC isolation and total RNA extraction

The PBMCs were isolated using Ficoll following standard methods. Frozen PBMCs isolated from the blood samples of the study animals were processed at the Biological Safety Level 3 laboratory at the Center for Comparative Medicine (CCM) at UC Davis. Each vial of frozen PBMC contained approximately 10^7 cells. These cells were defrosted and rapidly subjected to RNA extraction. The freezing buffer was washed off the PBMCs using 15 ml of Classical Gibco media (RPMI 1640, Life Technologies, NY), for each sample. Lysis buffer was added to the tubes containing PBMCs and the RNA was extracted following the RNeasy Mini Kit protocol (Qiagen Inc., Valencia, CA). The extracted RNA was stored overnight in a -20°C freezer after adding 10 μ L of NaOH and 250 μ L of 100% ethanol for precipitation.

4.4. cDNA synthesis and real-time polymerase chain reaction (q-PCR)

The extracted RNA samples were quantified prior to cDNA synthesis following the manufacturers' guidelines. Normalized concentrations of RNA samples were used for cDNA synthesis and q-PCR reactions. The primers for *IFNE* (Hs00703565-s1), *IL10* (Hs00174086 m1), *CD40* (Rh02621776-m1), *CXCL10* (Rh02788357-m1), *IL17A*

(Hs00174383-m1), *CD40L* (Rh02787995-m1), *IL12A* (Hs00168405-m1), *TLR2* (Rh02787279-s1), *CSF2* (Rh02621728-m1), *IL7* (Rh02621732-m1), *IL15* (Rh02621777-m1), *PPARG* (Rh02787676-m1), *TR4* (Hs00991824-m1), *IL23A* (Rh02872166-m1), *FAS* (*CD95*) (Rh02787979-m1), *IFNG* (Hs00989291-m1), *NRAMP1* (Rh02829150-mH), *IL13* (Rh03043053-m1), *IL4* (Rh02789319-m1), *IL5* (Rh03456659-u1), *FASL* (Rh02621724-m1), *CCL2* (Rh02787889-mH), *CD209* (Rh02788045-m1), *TNF* (Rh02789783-m1), and two different primers (Hs00167257-m1) and (Rh02829281-m1) for *NOS2A* were obtained from Applied Biosystems (Foster City, CA). The primers for *GAPDH* (forward, GCACCACCAACTGCTTAGCACC; reverse, TCTTCTGGGTG-GCAGTGATG; probe, TCGTGGGAAGGACTCATGACCACAGTCC) were designed, optimized, and validated by the Lucy Whittier Molecular Core Lab at the University of California Davis. The reaction was performed on the ABI ViiA 7 sequence detector (Applied Biosystems, CA) in tubes containing RT-qPCR master mix. Expression levels of all samples were normalized to that of a housekeeping gene, *GAPDH* (glyceraldehyde-3-phosphate dehydrogenase), and expressed as the relative difference.

4.5. Histopathology

Paraffin embedded blocks containing tissue samples from the right caudal lobe of the lungs of all the study animals were used to prepare histopathology slides using hematoxyline and eosin or trichrome blue staining at the Anatomic Pathology Service of the William R. Pritchard Veterinary Medical Teaching Hospital, University of California, Davis.

The Supplementary Material contains the raw data on TB outcomes for each animal, in each lung lobe, for each measure of TB severity; see *GranulomaCount.csv*, *GranulomaSize.csv*, *GranulomaVolume.csv*, *NonGranulomaVolume.csv*, and *CellCount.csv*. Definitions for the values in these data sets are provided below.

4.6. Statistical Analysis

4.6.1. Model Definition

We have five outcome variables per animal, $n \in \{1, \dots, N\}$, per lung lobe, $l \in \{1 \dots L\}$, which are: 1) a semi-quantitative granuloma count, $G_{[n,l]} \in \{0, 1\}$, where a value of 1 indicates more than 10 granulomas per sample or a miliary pattern, and 0 indicates 10 or fewer granulomas; 2) a semiquantitative characterization of the size of the largest granuloma, $S_{[n,l]} \in \{0, 1\}$, where a value of 1 indicates a granuloma size of 3mm or greater, and a value of 0 indicates a size of less than 3mm; 3) the log of the volume of granuloma lesions $V_{[n,l]} \in \mathbb{R}$; 4) the log of the volume of non-granuloma lesions $W_{[n,l]} \in \mathbb{R}$; and 5) the log of *Mycobacterium tuberculosis* load (CFU), $M_{[n,l]} \in \mathbb{R}$. A small constant was added to volume data to ensure that the log of 0 was not taken. Each of these outcome variables is taken directly from previously published work [63].

As is the case with the non-independence of TB pathogenesis across lung lobes within animals, our outcome variables within lung lobes are non-independent. Each of these outcome variables, however, contain slightly different information, in that differing genetic factors might have implications for the count versus size of granulomas, or implications for the nature of lesions as granulomatous versus non-granulomatous. We model these outcomes jointly using a multi-level hybrid Gaussian-Bernoulli regression model, so that the correlations, if any, between the regression parameters for each outcome variable can be estimated and used to improve inference within each sub-model. We use Hamiltonian Marcov Chain Monte Carlo (MCMC) simulation, implemented using the Stan v2.2 C++ library, to fit our model [91].

At each MCMC iteration we model:

$$G_{[n,l]} \sim \text{Bernoulli}(\text{logistic}(\lambda_{[n,l]})) \quad (1)$$

$$S_{[n,l]} \sim \text{Bernoulli}(\text{logistic}(\theta_{[n,l]})) \quad (2)$$

$$M_{[n,l]} \sim \text{Normal}(\psi_{[n,l]}, \sigma_M) \quad (3)$$

$$V_{[n,l]} \sim \text{Normal}(\phi_{[n,l]}, \sigma_V) \quad (4)$$

$$W_{[n,l]} \sim \text{Normal}(\kappa_{[n,l]}, \sigma_W) \quad (5)$$

where $\lambda_{[n,l]}$, $\theta_{[n,l]}$, $\psi_{[n,l]}$, $\phi_{[n,l]}$, and $\kappa_{[n,l]}$ are defined as functions of the expression levels, $X_{[n,t]}$, of a given gene, in a given animal, n , at a given point in time, t :

$$\lambda_{[n,l]} = \beta_{[1,l]} + \beta_{[2,l]} X_{[n,t]} \quad (6)$$

$$\theta_{[n,l]} = \beta_{[3,l]} + \beta_{[4,l]}X_{[n,t]} \quad (7)$$

$$\psi_{[n,l]} = \beta_{[5,l]} + \beta_{[6,l]}X_{[n,t]} \quad (8)$$

$$\phi_{[n,l]} = \beta_{[7,l]} + \beta_{[8,l]}X_{[n,t]} \quad (9)$$

$$\kappa_{[n,l]} = \beta_{[9,l]} + \beta_{[10,l]}X_{[n,t]} \quad (10)$$

It should be noted that a single predictor in animal n , the gene expression level, $X_{[n,t]}$ in PBMCs, is used to predict each outcome variable in each lung lobe. It should also be noted that the intercept ($\beta_{[1,l]}, \beta_{[3,l]}, \dots, \beta_{[9,l]}$) and slope ($\beta_{[2,l]}, \beta_{[4,l]}, \dots, \beta_{[10,l]}$) coefficients have unique values for each lobe, l . This allows for the relationship between gene expression and presence of granuloma to vary by lung lobe (an effect which is clearly visible in the raw data distributions). Finally, we note that we refit the model iteratively for each combination of gene and time, t , to yield an estimation of the usefulness of the expression levels of a given gene at a given time to predict the severity and form of *M. tuberculosis* infection at post-mortem analysis.

At each model iteration, we use a hierarchical model structure to estimate the value of the coefficient vector, $\beta_{[l]}$, while simultaneously pooling information across lung lobes, to yield coefficient estimates that describe the average relationship between gene expression levels and pathogenesis across lung lobe types, μ_β . We model:

$$\beta_{[l]} \sim \text{Multivariate Normal}(\mu_\beta, \Sigma) \quad (11)$$

where Σ is a variance-covariance matrix which allows for partial pooling of information across the parameters within and between each of the sub-models included in our analysis.

To complete the fully Bayesian model definition, we define weakly informative priors on each cell of the mean parameter vector, μ_β :

$$\mu_\beta \sim \text{Normal}(0, 10) \quad (12)$$

We define a prior on the variance-covariance matrix Σ , using a correlation matrix, ρ , multiplied on both sides by diagonal matrices of value ξ to scale the size of the variance terms:

$$\Sigma = \text{Diag}(\xi)\rho\text{Diag}(\xi) \quad (13)$$

We use weakly regularizing (half) Cauchy priors on the elements of ξ :

$$\xi \sim \text{Cauchy}(0, 2.5)T[0, \infty] \quad (14)$$

and the correlation matrix is given a prior of:

$$\rho \sim \text{LKJ}_{\text{corr}}(2) \quad (15)$$

which places an approximately uniform density across the off diagonal of the matrix. The LKJ_{corr} distribution is describe by [92], and is used in the Stan programming language as an alternative to Wishart-based variance-covariance matrix parameterizations, which Gelman and colleagues argue are often too restrictive for general use [93].

The standard deviation parameters for the Gaussian models are given weakly regularizing (half) Cauchy distributions as priors:

$$\sigma_M \sim \text{Cauchy}(0, 2.5)T[0, \infty] \quad (16)$$

$$\sigma_V \sim \text{Cauchy}(0, 2.5)T[0, \infty] \quad (17)$$

$$\sigma_W \sim \text{Cauchy}(0, 2.5)T[0, \infty] \quad (18)$$

4.6.2. Model Comparison

We compare models using the Watanabe-Akaike information criterion (WAIC) [66], which is a more fully-Bayesian generalization of the standard Akaike information theoretic criteria, AIC. Computed WAIC is defined as:

$$\text{WAIC} = -2(\text{lppd} - p_E) \quad (19)$$

The computed log pointwise posterior predictive density, $lppd$, is defined as:

$$lppd = \sum_{n=1}^N \log\left(\frac{1}{Q} \sum_{q=1}^Q Pr(Y_{[n,l]}|\Psi_{[n,l,q]})\right) \quad (20)$$

where $q \in \{1, \dots, Q\}$ references the index of simulations from the posterior distribution, with Q being the total number of saved simulations. The effective number of parameters, p_E is computed as:

$$p_E = \sum_{n=1}^N \text{Var}_{q=1}^Q(\log(Y_{[n,l]}|\Psi_{[n,l,q]})) \quad (21)$$

where the symbol $\text{Var}_{q=1}^Q$ represents the function to calculate the sample variance over the posterior simulations. The symbol $\Psi_{[n,l,q]}$ represents the model predictions (eg. $\lambda_{[n,l]}$, $\theta_{[n,l]}$, etc ...), and the symbol $Y_{[n,l]}$ represents the model data (eg. $G_{[n,l]}$, $S_{[n,l]}$, etc ...).

5. Acknowledgments

This research was funded by NIH grant #RR025871 and the Clinical and Translational Science Center's T32 program.

References

- [1] W. H. Organization, Global Tuberculosis Report 2013, World Health Organization, 2013.
- [2] G. P. Walsh, E. V. Tan, E. C. D. Cruz, R. M. Abalos, L. G. Villahermosa, L. J. Young, R. V. Cellona, J. B. Narareno, M. A. Horwitz, The Philippine cynomolgus monkey (*Macaca fascicularis*) provides a new nonhuman primate model of tuberculosis that resembles human disease, *Nature medicine* 2 (4) (1996) 430–436.
- [3] S. V. Capuano, D. A. Croix, S. Pawar, A. Zinovik, A. Myers, P. L. Lin, S. Bissel, C. Fuhrman, E. Klein, J. L. Flynn, Experimental *Mycobacterium tuberculosis* infection of cynomolgus macaques closely resembles the various manifestations of human *M. tuberculosis* infection, *Infection and immunity* 71 (10) (2003) 5831–5844.
- [4] W. Barclay, R. Anacker, W. Brehmer, W. Leif, E. Ribí, Aerosol-induced tuberculosis in subhuman primates and the course of the disease after intravenous BCG vaccination, *Infection and immunity* 2 (5) (1970) 574–582.
- [5] J. Flynn, S. Capuano, D. Croix, S. Pawar, A. Myers, A. Zinovik, E. Klein, Non-human primates: a model for tuberculosis research, *Tuberculosis* 83 (1) (2003) 116–118.
- [6] C. T. Ross, J. A. Weise, S. Bonnar, D. Nolin, J. Satkoski Trask, D. G. Smith, B. Ferguson, J. Ha, H. M. Kubisch, A. Vinson, et al., An empirical comparison of short tandem repeats (STRs) and single nucleotide polymorphisms (SNPs) for relatedness estimation in Chinese rhesus macaques (*Macaca mulatta*), *American journal of primatology* 76 (4) (2014) 313–324.
- [7] S. Marino, N. A. Cilfone, J. T. Mattila, J. J. Linderman, J. L. Flynn, D. E. Kirschner, Macrophage polarization drives granuloma outcome during *Mycobacterium tuberculosis* infection, *Infection and immunity* 83 (1) (2015) 324–338.
- [8] M. Roodgar, C. T. Ross, N. J. Kenyon, G. Marcelino, D. G. Smith, Inducible nitric oxide synthase (iNOS) regulatory region variation in non-human primates, *Infection, Genetics and Evolution* 31 (2015) 236–244.
- [9] M. Möller, E. G. Hoal, Current findings, challenges and novel approaches in human genetic susceptibility to tuberculosis, *Tuberculosis* 90 (2) (2010) 71–83.
- [10] R. Hernandez-Pando, T. Schön, E. Orozco, J. Serafin, I. Estrada-Garcia, Expression of inducible nitric oxide synthase and nitrotyrosine during the evolution of experimental pulmonary tuberculosis, *Experimental and Toxicologic Pathology* 53 (4) (2001) 257–265.
- [11] M. Kessler, R. Brown, Intraocular granuloma associated with disseminated tuberculosis in a rhesus monkey (*Macaca mulatta*), *The Journal of Zoo Animal Medicine* (1979) 122–124.
- [12] D. Zumpe, M. Silberman, R. Michael, Unusual outbreak of tuberculosis due to mycobacterium bovis in a closed colony of rhesus monkeys (macaca mulatta), *Laboratory animal science* 30 (2 Pt 1) (1980) 237–240.
- [13] S. Mahajan, H. K. Dkhar, V. Chandra, S. Dave, R. Nanduri, A. K. Janmeja, J. N. Agrewala, P. Gupta, *Mycobacterium tuberculosis* modulates macrophage lipid-sensing nuclear receptors PPAR γ and TR4 for survival, *The Journal of Immunology* 188 (11) (2012) 5593–5603.
- [14] A. M. Cooper, D. K. Dalton, T. A. Stewart, J. Griffin, D. Russell, I. Orme, Disseminated tuberculosis in interferon gamma gene-disrupted mice, *The Journal of experimental medicine* 178 (6) (1993) 2243–2247.
- [15] J. L. Flynn, J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, B. R. Bloom, An essential role for interferon gamma in resistance to *Mycobacterium tuberculosis* infection., *The Journal of experimental medicine* 178 (6) (1993) 2249–2254.
- [16] K. Takeda, T. Kawai, Y. Nakazawa, H. Komuro, K. Shoji, K. Morita, T. Katsuta, M. Yamamoto, I. Miyairi, Y. Ohya, et al., Augmentation of antitubercular therapy with interferon- γ in a patient with dominant partial interferon- γ receptor 1 deficiency, *Clinical Immunology*.
- [17] V. Lazarevic, A. J. Myers, C. A. Scanga, J. L. Flynn, CD40, but not CD40L, is required for the optimal priming of t cells and control of aerosol *M. tuberculosis* infection, *Immunity* 19 (6) (2003) 823–835.

- [18] M. S. Shey, E. Nemes, W. Whatney, M. de Kock, H. Africa, C. Barnard, M. van Rooyen, L. Stone, C. Riou, T. Kollmann, et al., Maturation of innate responses to mycobacteria over the first nine months of life, *The Journal of Immunology* (2014) 1400062.
- [19] N. P. Juffermans, A. Verbon, S. J. van Deventer, H. van Deutekom, J. T. Belisle, M. E. Ellis, P. Speelman, T. van der Poll, Elevated chemokine concentrations in sera of human immunodeficiency virus HIV-seropositive and HIV-seronegative patients with tuberculosis: a possible role for *Mycobacterial lipoarabinomannan*, *Infection and immunity* 67 (8) (1999) 4295–4297.
- [20] M. Gonzalez-Juarrero, J. M. Hattle, A. Izzo, A. P. Junqueira-Kipnis, T. S. Shim, B. C. Trapnell, A. M. Cooper, I. M. Orme, Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control *Mycobacterium tuberculosis* infection, *Journal of leukocyte biology* 77 (6) (2005) 914–922.
- [21] J. Szeliga, D. S. Daniel, C.-H. Yang, Z. Sever-Chroneos, C. Jagannath, Z. C. Chrones, Granulocyte–macrophage colony stimulating factor-mediated innate responses in tuberculosis, *Tuberculosis* 88 (1) (2008) 7–20.
- [22] G. M. Klug-Micu, S. Stenger, A. Sommer, P. T. Liu, S. R. Krutzik, R. L. Modlin, M. Fabri, CD40 ligand and Interferon- γ induce an antimicrobial response against *Mycobacterium tuberculosis* in human monocytes, *Immunology* 139 (1) (2013) 121–128.
- [23] M. K. Tripathi, M. Yasir, V. S. Gurjar, P. Bose, A. Dubey, R. Shrivastava, Insights from the molecular docking of hydrolytic products of methyl-iso-cyanate (MIC) to inhibition of human immune proteins, *Interdisciplinary Sciences: Computational Life Sciences* (2015) 1–8.
- [24] O. Filipe-Santos, J. Bustamante, M. H. Haverkamp, E. Vinolo, C.-L. Ku, A. Puel, D. M. Frucht, K. Christel, H. Von Bernuth, E. Jouanguy, et al., X-linked susceptibility to mycobacteria is caused by mutations in nemo impairing cd40-dependent il-12 production, *The Journal of experimental medicine* 203 (7) (2006) 1745–1759.
- [25] M. J. Maeurer, P. Trinder, G. Hommel, W. Walter, K. Freitag, D. Atkins, S. Störkel, Interleukin-7 or Interleukin-15 enhances survival of *Mycobacterium tuberculosis*-infected mice, *Infection and immunity* 68 (5) (2000) 2962–2970.
- [26] M. Feske, R. J. Nudelman, M. Medina, J. Lew, M. Singh, J. Couturier, E. A. Gravis, D. E. Lewis, Enhancement of human antigen-specific memory t-cell responses by Interleukin-7 may improve accuracy in diagnosing tuberculosis, *Clinical and Vaccine Immunology* 15 (10) (2008) 1616–1622.
- [27] L. Rane, S. Rahman, I. Magalhaes, R. Ahmed, M. Spångberg, I. Kondova, F. Verreck, J. Andersson, S. Brighenti, M. Maeurer, Increased (6 exon) Interleukin-7 production after *M. tuberculosis* infection and soluble Interleukin-7 receptor expression in lung tissue, *Genes and immunity* 12 (7) (2011) 513–522.
- [28] G. Zissel, I. Bäumer, M. Schlaak, J. Müller-Quernheim, In vitro release of Interleukin-15 by broncho-alveolar lavage cells and peripheral blood mononuclear cells from patients with different lung diseases., *European cytokine network* 11 (1) (2000) 105–12.
- [29] F. Abebe, T. Mustafa, A. Nerland, G. Bjune, Cytokine profile during latent and slowly progressive primary tuberculosis: a possible role for Interleukin-15 in mediating clinical disease, *Clinical & Experimental Immunology* 143 (1) (2006) 180–192.
- [30] J. Turner, C. D'souza, J. Pearl, P. Marietta, M. Noel, A. Frank, R. Appelberg, I. Orme, A. Cooper, CD8-and CD95/95L-dependent mechanisms of resistance in mice with chronic pulmonary tuberculosis, *American journal of respiratory cell and molecular biology* 24 (2) (2001) 203–209.
- [31] S. A. Khader, G. K. Bell, J. E. Pearl, J. J. Fountain, J. Rangel-Moreno, G. E. Cilley, F. Shen, S. M. Eaton, S. L. Gaffen, S. L. Swain, et al., IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during *Mycobacterium tuberculosis* challenge, *Nature immunology* 8 (4) (2007) 369–377.
- [32] S. A. Khader, J. E. Pearl, K. Sakamoto, L. Gilmartin, G. K. Bell, D. M. Jelley-Gibbs, N. Ghilardi, A. M. Cooper, et al., IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN- γ responses if IL-12p70 is available, *The Journal of Immunology* 175 (2) (2005) 788–795.
- [33] M. Zhang, M. Gately, E. Wang, J. Gong, S. Wolf, S. Lu, R. Modlin, P. Barnes, Interleukin-12 at the site of disease in tuberculosis, *Journal of Clinical Investigation* 93 (4) (1994) 1733.
- [34] J. Flynn, M. M. Goldstein, K. J. Triebold, J. Sypek, S. Wolf, B. R. Bloom, IL-12 increases resistance of BALB/c mice to *Mycobacterium tuberculosis* infection., *The Journal of Immunology* 155 (5) (1995) 2515–2524.
- [35] C. Hölscher, R. A. Atkinson, B. Arendse, N. Brown, E. Myburgh, G. Alber, F. Brombacher, A protective and agonistic function of il-12p40 in mycobacterial infection, *The Journal of Immunology* 167 (12) (2001) 6957–6966.
- [36] A. Nolan, E. Fajardo, M. L. Huie, R. Condos, A. Pooran, R. Dawson, K. Dheda, E. Bateman, W. N. Rom, M. D. Weiden, Increased production of IL-4 and IL-12p40 from bronchoalveolar lavage cells are biomarkers of *Mycobacterium tuberculosis* in the sputum, *PloS one* 8 (3) (2013) e59461.
- [37] G. Seah, G. Scott, G. Rook, Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis, *Journal of Infectious Diseases* 181 (1) (2000) 385–389.
- [38] I. M. Orme, A. D. Roberts, J. P. Griffin, J. Abrams, Cytokine secretion by CD4 T lymphocytes acquired in response to *Mycobacterium tuberculosis* infection, *The Journal of Immunology* 151 (1) (1993) 518–525.
- [39] H. L. Collins, U. E. Schaible, S. H. Kaufmann, Early IL-4 induction in bone marrow lymphoid precursor cells by *Mycobacterial lipoarabinomannan*, *The Journal of Immunology* 161 (10) (1998) 5546–5554.
- [40] R. Benjamin, A. Banerjee, S. R. Sunder, S. Gaddam, V. L. Valluri, S. Banerjee, Discordance in CD4+ T-cell levels and viral loads with co-occurrence of elevated peripheral TNF- α and IL-4 in newly diagnosed HIV-TB co-infected cases, *PloS one* 8 (8) (2013) e70250.
- [41] X. Li, Y. Yang, F. Zhou, Y. Zhang, H. Lu, Q. Jin, L. Gao, SLC11A1 (NRAMP1) polymorphisms and tuberculosis susceptibility: updated systematic review and meta-analysis, *PLoS One* 6 (1) (2011) e15831.
- [42] D. Malo, K. Vogan, S. Vidal, J. Hu, M. Cellier, E. Schurr, A. Fuks, N. Bumstead, K. Morgan, P. Gros, Haplotype mapping and sequence analysis of the mouse Nramp gene predict susceptibility to infection with intracellular parasites, *Genomics* 23 (1) (1994) 51–61.
- [43] S. M. Vidal, D. Malo, K. Vogan, E. Skamene, P. Gros, Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg, *Cell* 73 (3) (1993) 469–485.
- [44] R. J. North, R. LaCourse, L. Ryan, P. Gros, Consequence of Nramp1 deletion to *Mycobacterium tuberculosis* infection in mice, *Infection and immunity* 67 (11) (1999) 5811–5814.
- [45] R. Bellamy, C. Ruwende, T. Corrah, K. P. McAdam, H. C. Whittle, A. V. Hill, Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans, *New England Journal of Medicine* 338 (10) (1998) 640–644.
- [46] S. Gruenheid, E. Pinner, M. Desjardins, P. Gros, Natural resistance to infection with intracellular pathogens: the Nramp1 protein is recruited

- to the membrane of the phagosome, *The Journal of experimental medicine* 185 (4) (1997) 717–730.
- [47] D. M. Underhill, A. Ozinsky, K. D. Smith, A. Aderem, Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages, *Proceedings of the National Academy of Sciences* 96 (25) (1999) 14459–14463.
- [48] T. K. Means, S. Wang, E. Lien, A. Yoshimura, D. T. Golenbock, M. J. Fenton, Human toll-like receptors mediate cellular activation by *Mycobacterium tuberculosis*, *The Journal of Immunology* 163 (7) (1999) 3920–3927.
- [49] T. Mustafa, S. Phyu, R. Nilsen, G. Bjune, R. Jonsson, Increased expression of Fas ligand on *Mycobacterium tuberculosis* infected macrophages: a potential novel mechanism of immune evasion by *Mycobacterium tuberculosis*?, *Inflammation* 23 (6) (1999) 507–521.
- [50] W. L. Ling, L. J. Wang, J. C. Pong, A. S. Lau, J. C. Li, A role for Interleukin-17A in modulating intracellular survival of *Mycobacterium bovis* bacillus Calmette–Guérin in murine macrophages, *Immunology* 140 (3) (2013) 323–334.
- [51] A. S. Wareham, J. A. Tree, P. D. Marsh, P. D. Butcher, M. Dennis, S. A. Sharpe, Evidence for a role for Interleukin-17, Th17 cells and iron homeostasis in protective immunity against tuberculosis in cynomolgus macaques, *PLoS one* 9 (2) (2014) e88149.
- [52] J. S. Friedland, R. J. Shattock, G. E. Griffin, Phagocytosis of *Mycobacterium tuberculosis* or particulate stimuli by human monocytic cells induces equivalent monocyte chemotactic protein-1 gene expression, *Cytokine* 5 (2) (1993) 150–156.
- [53] A. Kipnis, R. J. Basaraba, I. M. Orme, A. M. Cooper, Role of chemokine ligand 2 in the protective response to early murine pulmonary tuberculosis, *Immunology* 109 (4) (2003) 547–551.
- [54] Z. Hasan, J. M. Cliff, H. M. Dockrell, B. Jamil, M. Irfan, M. Ashraf, R. Hussain, CCL2 responses to *Mycobacterium tuberculosis* are associated with disease severity in tuberculosis, *PLoS One* 4 (12) (2009) e8459.
- [55] M. Ganachari, H. Guio, N. Zhao, P. O. Flores-Villanueva, Host gene-encoded severe lung TB: from genes to the potential pathways, *Genes and immunity* 13 (8) (2012) 605–620.
- [56] U. S. Gautam, S. Mehra, M. H. Ahsan, X. Alvarez, T. Niu, D. Kaushal, Role of TNF in the altered interaction of dormant *Mycobacterium tuberculosis* with host macrophages, *PLoS one* 9 (4) (2014) e95220.
- [57] O. J. Kwon, J. H. Kim, H. C. Kim, G. Y. Suh, J. W. Park, M. P. Chung, H. Kim, C. H. Rhee, Nitric oxide expression in airway epithelial cells in response to tubercle bacilli stimulation, *Respirology* 3 (2) (1998) 119–124.
- [58] I. Garcia, R. Guler, D. Vesin, M. L. Ollerios, P. Vassalli, Y. Chvatchko, M. Jacobs, B. Ryffel, Lethal *Mycobacterium bovis* Bacillus Calmette Guérin infection in nitric oxide synthase 2-deficient mice: cell-mediated immunity requires nitric oxide synthase 2, *Laboratory investigation* 80 (9) (2000) 1385–1397.
- [59] N. Kapoor, Y. Narayana, S. A. Patil, K. N. Balaji, Nitric oxide is involved in *Mycobacterium bovis* Bacillus Calmette–Guérin–activated Jagged1 and Notch1 signaling, *The Journal of Immunology* 184 (6) (2010) 3117–3126.
- [60] D. Gupta, S. Sharma, J. Singhal, A. T. Satsangi, C. Antony, K. Natarajan, Suppression of TLR2-induced IL-12, reactive oxygen species, and inducible nitric oxide synthase expression by *Mycobacterium tuberculosis* antigens expressed inside macrophages during the course of infection, *The Journal of Immunology* 184 (10) (2010) 5444–5455.
- [61] L. Tailleux, O. Schwartz, J.-L. Herrmann, E. Pivert, M. Jackson, A. Amara, L. Legres, D. Dreher, L. P. Nicod, J. C. Gluckman, et al., DC-SIGN is the major *Mycobacterium tuberculosis* receptor on human dendritic cells, *The Journal of experimental medicine* 197 (1) (2003) 121–127.
- [62] T. B. Geijtenbeek, S. J. van Vliet, E. A. Koppel, M. Sanchez-Hernandez, C. M. Vandenbroucke-Grauls, B. Appelmeij, Y. van Kooyk, Mycobacteria target DC-SIGN to suppress dendritic cell function, *The Journal of experimental medicine* 197 (1) (2003) 7–17.
- [63] P. A. Luciw, K. L. Oslund, X.-w. Yang, L. Adamson, R. Ravindran, D. R. Canfield, R. Tarara, L. Hirst, M. Christensen, N. W. Lerche, et al., Stereological analysis of bacterial load and lung lesions in nonhuman primates (rhesus macaques) experimentally infected with *Mycobacterium tuberculosis*, *American Journal of Physiology-Lung Cellular and Molecular Physiology* 301 (5) (2011) L731–L738.
- [64] A. A. Alizadeh, D. T. Ross, C. M. Perou, M. van de Rijn, Towards a novel classification of human malignancies based on gene expression patterns, *The Journal of pathology* 195 (1) (2001) 41–52.
- [65] R. B. Millar, M. J. Anderson, Remedies for pseudoreplication, *Fisheries Research* 70 (2) (2004) 397–407.
- [66] A. Gelman, J. Hwang, A. Vehtari, Understanding predictive information criteria for Bayesian models, *Statistics and Computing* (2013) 1–20.
- [67] P. L. Lin, S. Pawar, A. Myers, A. Pegu, C. Fuhrman, T. A. Reinhart, S. V. Capuano, E. Klein, J. L. Flynn, Early events in *Mycobacterium tuberculosis* infection in cynomolgus macaques, *Infection and immunity* 74 (7) (2006) 3790–3803.
- [68] S. Kanthaswamy, J. Ng, C. T. Ross, J. S. Trask, D. G. Smith, V. S. Buffalo, J. N. Fass, D. Lin, Identifying human-rhesus macaque gene orthologs using heterospecific SNP probes, *Genomics* 101 (1) (2013) 30–37.
- [69] H. K. Dkhar, R. Nanduri, S. Mahajan, S. Dave, A. Saini, A. K. Somavarapu, A. Arora, R. Parkesh, K. G. Thakur, S. Mayilraj, et al., *Mycobacterium tuberculosis* keto-mycolic acid and macrophage nuclear receptor TR4 modulate foamy biogenesis in granulomas: a case of a heterologous and noncanonical ligand-receptor pair, *The Journal of Immunology* 193 (1) (2014) 295–305.
- [70] Y. Xu, E. Yang, Q. Huang, W. Ni, C. Kong, G. Liu, G. Li, H. Su, H. Wang, PPE57 induces activation of macrophages and drives Th1-type immune responses through TLR2, *Journal of Molecular Medicine* (2015) 1–18.
- [71] A. Campos-Neto, P. Ovendale, T. Bement, T. A. Koppi, W. C. Fanslow, M. A. Rossi, M. R. Alderson, Cutting edge: CD40 ligand is not essential for the development of cell-mediated immunity and resistance to *Mycobacterium tuberculosis*, *The Journal of Immunology* 160 (5) (1998) 2037–2041.
- [72] S. Stenger, R. L. Modlin, T cell mediated immunity to *Mycobacterium tuberculosis*, *Current opinion in microbiology* 2 (1) (1999) 89–93.
- [73] A. Roberts, I. M. Orme, CD95 expression in aged mice infected with tuberculosis, *Infection and immunity* 66 (10) (1998) 5036–5040.
- [74] T. Mustafa, H. G. Wiker, O. Mørkve, L. Sviland, Differential expression of mycobacterial antigen MPT64, apoptosis and inflammatory markers in multinucleated giant cells and epithelioid cells in granulomas caused by *Mycobacterium tuberculosis*, *Virchows Archiv* 452 (4) (2008) 449–456.
- [75] S. El-Masry, M. Lotfy, W. Nasif, I. El-Kady, M. Al-Badrawy, Elevated serum level of interleukin IL-18, interferon IFN- γ and soluble Fas in patients with pulmonary complications in tuberculosis, *Acta microbiologica et immunologica Hungarica* 54 (1) (2007) 65–77.
- [76] T. Mustafa, S. J. Mogga, S. G. Mfinanga, O. Mørkve, L. Sviland, Significance of Fas and Fas ligand in tuberculous lymphadenitis, *Immunology* 114 (2) (2005) 255–262.
- [77] M. Roodgar, A. Lackner, D. Kaushal, S. Sankaran, S. Dandekar, J. Satkoski Trask, C. Drake, D. G. Smith, Expression levels of 10 candidate

- genes in lung tissue of vaccinated and TB-infected cynomolgus macaques, *Journal of medical primatology* 42 (3) (2013) 161–164.
- [78] J. T. Mattila, O. O. Ojo, D. Kepka-Lenhart, S. Marino, J. H. Kim, S. Y. Eum, L. E. Via, C. E. Barry, E. Klein, D. E. Kirschner, et al., Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms, *The Journal of Immunology* 191 (2) (2013) 773–784.
 - [79] H.-S. Choi, P. R. Rai, H. W. Chu, C. Cool, E. D. Chan, Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis, *American journal of respiratory and critical care medicine* 166 (2) (2002) 178–186.
 - [80] S. Roy, S. Sharma, M. Sharma, R. Aggarwal, M. Bose, Induction of nitric oxide release from the human alveolar epithelial cell line A549: an in vitro correlate of innate immune response to *Mycobacterium tuberculosis*, *Immunology* 112 (3) (2004) 471–480.
 - [81] M. Alvarez-Puebla, R. J. Olaguibel, E. Almudevar, A. Echegoyen, C. B. de Esteban, K. Cambra, Cutoff point for exhaled nitric oxide corresponding to 3% sputum eosinophils., *Journal of investigational allergology & clinical immunology* 25 (2) (2014) 107–111.
 - [82] N. L.-S. Tang, H. P. Y. Fan, K. C. Chang, J. K. L. Ching, K. P. S. Kong, W. W. Yew, K. M. Kam, C. C. Leung, C. M. Tam, J. Blackwell, et al., Genetic association between a chemokine gene CXCL-10 (IP-10, interferon gamma inducible protein 10) and susceptibility to tuberculosis, *Clinica Chimica Acta* 406 (1) (2009) 98–102.
 - [83] V. O. Kasproicz, J. E. Mitchell, S. Chetty, P. Govender, K. Huang, H. A. Fletcher, D. P. Webster, S. Brown, A. Kasmar, K. Millington, et al., A molecular assay for sensitive detection of pathogen-specific T-cells, *PloS one* 6 (8) (2011) e20606–e20606.
 - [84] M. Ahmed Yassin, R. Petrucci, K. T. Garie, G. Harper, I. Arbide, M. Aschalew, Y. Merid, Z. Kebede, A. A. Bawazir, N. M. Abuamer, et al., Can interferon-gamma or interferon-gamma-induced-protein-10 differentiate tuberculosis infection and disease in children of high endemic areas?, *PLoS ONE* 6 (9).
 - [85] R. Simeone, F. Sayes, O. Song, M. I. Gröschel, P. Brodin, R. Brosch, L. Majlessi, P. Salgame, Cytosolic access of *Mycobacterium tuberculosis*: Critical impact of phagosomal acidification control and demonstration of occurrence in vivo., *PLoS pathogens* 11 (2) (2015) e1004650–e1004650.
 - [86] M. Spigelman, H. D. Donoghue, Z. Abdeen, S. Ereqat, I. Sarie, C. L. Greenblatt, I. Pap, I. Szikossy, I. Hershkovitz, G. K. Bar-Gal, et al., Evolutionary changes in the genome of *Mycobacterium tuberculosis* and the human genome from 9000 years bp until modern times, *Tuberculosis*.
 - [87] L. Wu, H. Deng, Y. Zheng, M. Mansjö, X. Zheng, Y. Hu, B. Xu, An association study of NRAMP1, VDR, MBL and their interaction with the susceptibility to tuberculosis in a Chinese population, *International Journal of Infectious Diseases* 38 (2015) 129–135.
 - [88] D. M. Higgins, J. Sanchez-Campillo, A. G. Rosas-Taraco, J. R. Higgins, E. J. Lee, I. M. Orme, M. Gonzalez-Juarrero, Relative levels of M-CSF and GM-CSF influence the specific generation of macrophage populations during infection with *Mycobacterium tuberculosis*, *The Journal of Immunology* 180 (7) (2008) 4892–4900.
 - [89] K. Braun, J. Wolfe, S. Kiazzyk, M. K. Sharma, Evaluation of host genetics on outcome of tuberculosis infection due to differences in killer immunoglobulin-like receptor gene frequencies and haplotypes, *BMC genetics* 16 (1) (2015) 63.
 - [90] S. Kanthaswamy, J. S. Trask, C. T. Ross, A. Kou, P. Houghton, D. G. Smith, N. Lerche, A large-scale SNP-based genomic admixture analysis of the captive rhesus macaque colony at the California National Primate Research Center, *American journal of primatology* 74 (8) (2012) 747–757.
 - [91] Stan Development Team, Stan: A C++ library for probability and sampling, version 2.2 (2013). URL <http://mc-stan.org/>
 - [92] D. Lewandowski, D. Kurowicka, H. Joe, Generating random correlation matrices based on vines and extended onion method, *Journal of multivariate analysis* 100 (9) (2009) 1989–2001.
 - [93] T. Tokuda, B. Goodrich, I. Van Mechelen, A. Gelman, F. Tuerlinckx, Visualizing distributions of covariance matrices, Tech. rep., Technical report, University of Leuven, Belgium and Columbia University, USA. URL <http://www.stat.columbia.edu/~gelman/research/unpublished/Visualization.pdf>. (Cited on pages 114, 116, 117 and 119.) (2011).

6. Figures





Figure 1: Quantified expression levels (Y-axis) of several of the genes investigated in this study, pre-infection (11-05-2008), at several dates post-infection (01-05-2009, 02-03-2009, 03-02-2009, 04-01-2009), and at time of euthanasia. Each animal's gene expression over time is represented by a unique color. Quantification could not be completed for all animals at all dates, leading to some cases of missing data. Across these sub-figures, we note that some genes (e.g. *TNF*) show consistent temporal trends across animals; other genes, however, show no overall temporal pattern in expression, even though their expression levels may be indicative of the severity TB infection (See Figure 2).




FASL-E-eps-converted-to.pdf

IL10-E-eps-converted-to.pdf

(e) *FASL*

(f) *IL10*



IP10-E-eps-converted-to.pdf

IFNE-E-eps-converted-to.pdf

(g) *IP10*

(h) *IFNE*







Figure 2: Caterpillar plots representing the associations between gene expression levels at various dates and quantitative measures of TB severity at euthanasia. Each subfigure is unique to a given gene, and each subplot within each subfigure is unique to a given quantitative measure of TB severity at euthanasia (vertical axis) for a given date of gene expression quantification (horizontal axis). The black points represent the posterior mean and the vertical grey bars indicate the central 95% posterior credibility intervals. The horizontal black lines represent the value of zero, or no effect. Null effects are typically close to zero, with confidence intervals that overlap zero. Reliable effects have confidence intervals that don't overlap zero, or do so only slightly. To be confident that an effect is actually non-zero, it is also useful to see if the effect is observed across the majority of the five outcome variables, and if the effect is part of a temporal trend.








Figure 3: Results of formal model comparison using WAIC. Each block represents a date when gene expression levels were quantified: A) 11/05/2008, B) 01/05/2009, C) 02/03/2009, D) 03/02/2009, E) 04/01/2009, F) Time of euthanasia. Each vertical column illustrates the information theoretic support that the specified gene (on the vertical axis) is the gene whose expression levels best predict a proxy of TB severity (on the horizontal axis). The column labels: G, S, M, V, and W, correspond to granuloma count in sections of lung, max granuloma size, granulomatous lesion volume, non-granulomatous lesion volume, and TB cell count, respectively. Increasing intensity of the red color indicates increasing information theoretic support. The quantitative results of the information theoretic model comparison used to generate this figure are included as Supplementary Materials. The “-” symbol indicates the performance of the null model, which does not include gene expression levels as a predictor; it should be noted that the null model has almost no information theoretic support in any of the model comparisons, meaning that use of gene expression levels to predict TB severity almost universally improves predictive inference. Consistent support for a given gene across proxies for TB severity and time periods provides good evidence that there exists a relationship between TB pathogenesis and gene expression levels.




Figure 4: Multifocally in the lung, there were individual and coalescing granulomas which ranged from approximately 200 to greater than 1000 µm in diameter. Granulomas were characterized by central areas which varied from having closely apposed epithelioid macrophages to necrosis consisting of intense eosinophilia, karyorrhexis, and karyolysis with basophilic hyalinized foci of mineralization (35446, b) or without basophilic hyalinized foci of mineralization (35414, a). The central region of granulomas were surrounded by areas of *necrosis* in animals that exhibited severe and active TB (c) or *fibrosis* in animals that exhibited less severe disease and more successfully controlled the infection (d). Mainly at the periphery of granulomas there was a primarily mononuclear inflammatory cell infiltrate composed of varying numbers of lymphocytes, plasma cells, histiocytes and rare multinucleated giant cells which were more sparsely distributed. An outer rim of fibrosis (encapsulation) delineated the granulomas from pulmonary parenchyma. Degree of severity was based on the percent of pulmonary parenchyma affected by this chronic inflammatory process, size and number of granuloma. 35710 was least affected; granulomas for this case were also smaller, see [63]. 36727 was most extensively affected with granulomas also in eyes and brain.




Figure 5: a) 35414 central area of caseous necrosis with margin of macrophages, multinucleated giant cells, and lymphocytes surrounded by fibrous connective tissue. b) 35446 central area of necrosis surrounded by fibrous connective tissue. c) 35603 central cavity containing mineralized material with margin of necrotic cells, surrounded by macrophages, distinct multinucleated giant cells and lymphocytes surrounded by patchy multifocal areas of fibrous connective tissue. d) 35710 central cavity containing mineralized material surrounded by macrophages, distinct multinucleated giant cells and lymphocytes surrounded by distinct area of fibrous connective tissue. e) 36365 central area of extensive necrosis surrounded by macrophages, lymphocyte, and distinct multinucleated giant cells surrounded by distinct fibrous connective tissue. f) 36727 central area of extensive necrosis with margin of macrophages, lymphocytes multinucleated giant cells surrounded by distinct fibrous connective tissue.